Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of childhood ALL. The early T-precursor (ETP-ALL) subset is characterized by an immature T-cell phenotype, chemoresistance, and high rates of induction failure. MERTK receptor tyrosine kinase is ectopically expressed in half of T-ALLs, par...

Full description

Bibliographic Details
Main Authors: Ryan J. Summers, Juhi Jain, Eleana Vasileiadi, Brittany Smith, Madison L. Chimenti, Tsz Y. Yeung, James Kelvin, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Jeffrey W. Tyner, Erik C. Dreaden, Deborah DeRyckere, Douglas K. Graham
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
ETP-ALL
small molecule inhibitor
MERTK
BCL-2
MRX-2843
Online Access:https://www.mdpi.com/2072-6694/14/24/6142

Similar Items

Similar Items